...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

Good post tada - Could you give me some background on the following?

ZCC owns some assets, which are about 75 million Royalty Preferred Shares of a company called Resverlogix and an operating company called Zenith Epigenetics Ltd also known as ZEL and some of the 1500 molecules that have the best opportunity to become future drugs. Depending on the day and the need for money some of the molecules get moved between ZCC and ZEL to secure whatever amount of loan is outstanding. The entire 1500 molecules were inside of ZEL at one point which formed the IP of ZEL."

I am not disagreeing with this just didn't know it so would appreciate if you could direct me to where this came from so I can get more informed. I never knew any molecules were moving between ZEL and ZCC. I thought ZEL held them all. ZCC has no loan outstanding and has $2.5 million in Promissory Notes to four persons. About half of this is to DM. The portion with DM and a relative of his is secured by all of the company's assets while the portion with the other two parties is unsecured. I don't see a need for molecules being transferred. Please give me some direction.

 

 

Share
New Message
Please login to post a reply